Haleon plc (NYSE:HLN) Shares Acquired by Creative Planning

Creative Planning increased its holdings in Haleon plc (NYSE:HLN) by 15.2% during the third quarter, HoldingsChannel.com reports. The fund owned 285,227 shares of the company’s stock after buying an additional 37,566 shares during the period. Creative Planning’s holdings in Haleon were worth $3,018,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of HLN. AE Wealth Management LLC increased its stake in Haleon by 6.1% in the 2nd quarter. AE Wealth Management LLC now owns 19,199 shares of the company’s stock valued at $159,000 after buying an additional 1,098 shares during the period. Cardinal Capital Management increased its stake in Haleon by 2.5% in the 2nd quarter. Cardinal Capital Management now owns 46,231 shares of the company’s stock valued at $382,000 after buying an additional 1,140 shares during the period. Endowment Wealth Management Inc. increased its stake in Haleon by 9.9% in the 2nd quarter. Endowment Wealth Management Inc. now owns 12,867 shares of the company’s stock valued at $106,000 after buying an additional 1,161 shares during the period. Portside Wealth Group LLC increased its stake in Haleon by 2.7% in the 2nd quarter. Portside Wealth Group LLC now owns 44,985 shares of the company’s stock valued at $372,000 after buying an additional 1,182 shares during the period. Finally, Hexagon Capital Partners LLC increased its stake in Haleon by 18.5% in the 3rd quarter. Hexagon Capital Partners LLC now owns 7,933 shares of the company’s stock valued at $84,000 after buying an additional 1,238 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Stock Performance

NYSE:HLN opened at $9.85 on Friday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a fifty-two week low of $7.70 and a fifty-two week high of $10.80. The stock has a market cap of $44.98 billion, a PE ratio of 32.83, a price-to-earnings-growth ratio of 2.90 and a beta of 0.26. The firm’s fifty day simple moving average is $10.23 and its 200-day simple moving average is $9.20.

Haleon (NYSE:HLN) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The business had revenue of $3.50 billion during the quarter, compared to analysts’ expectations of $3.55 billion. During the same quarter in the prior year, the firm earned $0.08 earnings per share. Analysts expect that Haleon plc will post 0.46 earnings per share for the current fiscal year.

Haleon Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which was paid on Thursday, September 19th. Investors of record on Friday, August 16th were given a $0.0514 dividend. The ex-dividend date was Friday, August 16th. This represents a dividend yield of 1.6%. Haleon’s dividend payout ratio is presently 33.33%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on HLN. The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Berenberg Bank initiated coverage on shares of Haleon in a research note on Tuesday, August 6th. They set a “buy” rating on the stock. Finally, Morgan Stanley upped their price target on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Haleon currently has an average rating of “Buy” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.